Asian Diabetes Outcomes Prevention Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2400 participants.

Also called NCT04286399

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04286399
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04286399. Randomized; no masking; primary purpose treatment. Start 2019-07-01 (actual); primary completion 2022-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Asian Diabetes Outcomes Prevention Trial
Acronym
ADOPT
Condition
Diabetes Mellitus
Condition
Cardiovascular Diseases
Intervention (Drug)
Renin-angiotensin-aldosterone system inhibitors
Intervention (Drug)
Beta blocker
Intervention (Drug)
SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Lead sponsor
National Heart Centre Singapore (class: other)
Collaborator
Singapore General Hospital (class: other)
Collaborator
Mackay Memorial Hospital (class: other)
Collaborator
National Taiwan University Hospital (class: other)
Collaborator
Peking University People's Hospital (class: other)
Collaborator
Medanta, The Medicity, India (class: other)
Collaborator
Public Health Foundation of India (class: other)
Collaborator
Putrajaya Hospital, Malaysia (class: not stated)
Collaborator
Universiti Teknologi Mara (class: other)

Record details

Record id
cardio:ct-nct04286399
Content hash
7caaf55f70b365d133f68284f8a7a258f362d5af520e17bf7be5e715bd7d1d6b